SGR-2921 is under clinical development by Schrodinger and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SGR-2921’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SGR-2921 overview
SGR-2921 is under development for the treatment of relapsed or refractory acute myeloid leukemia, myelodysplastic syndrome and colorectal cancer. It is administered through oral route. The drug candidate acts by targeting cell division cycle 7-related protein kinase (Cdc7) and is being developed based on the Schrodinger artificial intelligence (AI) technology.
Schrodinger overview
Schrodinger is a healthcare technology company that provides software solutions for drug discovery. The company offers a computational platform designed with predictive modeling, data analytics and collaboration applicable to molecular discovery. Its pipeline products include SGR-1505 (MALT1) against non-Hodgkin’s lymphoma, SGR-2921 (CDC7) to treat hematological cancers and solid tumors and SGR-3515 (Wee1) for gynecological cancers, and LRRK2 for Neurology and SOS1 for cancers and others. Schrodinger‘s other products include small molecule products, biological drug discovery and material science products. It provides training, documentation and support services. The company operates through offices in the US, Germany, Japan, Ireland, the UK, India, China and South Korea. Schrodinger is headquartered in New York City, New York, the US.
For a complete picture of SGR-2921’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
